{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:38:51Z","timestamp":1787593131183,"version":"build-2736575974"},"reference-count":36,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2023,5,1]]},"abstract":"<jats:p>\n                    In this study, we assessed the potential of bacteriocins and their\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    synergistic effects in combination with anti-tuberculosis drugs against\n                    <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                    . We evaluated the\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    activity of chemically synthesized bacteriocins in combination with rifampicin (RIF), ofloxacin, and moxifloxacin against the reference\n                    <jats:italic toggle=\"yes\">M. tuberculosis<\/jats:italic>\n                    H37Rv and a clinical-resistant strain. We first screened the bacteriocin PARAGEN collection and found active bacteriocins. We then determined their minimal inhibitory concentration (MIC), minimal bactericidal concentration, and their fractional inhibitory index by the checkerboard microdilution assay. Remarkably, we identified four bacteriocins with interesting antimycobacterial activity alone and in combinations with RIF, ofloxacin, and moxifloxacin, with significant reduction of the MIC that showed impressive synergistic effects against the susceptible and resistant clinical strains. In conclusion, our preliminary results show promising bacteriocins candidate used in a synergistic combination with anti-tuberculosis drugs and emphasize the need for combined therapy as a new strategy to enhance the activity of existing drugs, which may confer very promising therapeutic benefits against\n                    <jats:italic toggle=\"yes\">M. tuberculosis<\/jats:italic>\n                    .\n                  <\/jats:p>","DOI":"10.1089\/mdr.2021.0429","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T12:00:32Z","timestamp":1658232032000},"page":"165-174","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Promising Antimicrobial Activity and Synergy of Bacteriocins Against\n                    <i>Mycobacterium tuberculosis<\/i>"],"prefix":"10.1177","volume":"29","author":[{"given":"Anandi","family":"Martin","sequence":"first","affiliation":[{"name":"Syngulon, Seraing, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Bland","sequence":"additional","affiliation":[{"name":"Syngulon, Seraing, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Rodriguez-Villalobos","sequence":"additional","affiliation":[{"name":"Microbiology Department, Cliniques Universitaires Saint-Luc, Universit\u00e9 Catholique de Louvain (UCLouvain), Brussels, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Gala","sequence":"additional","affiliation":[{"name":"Center for Applied Molecular Technologies (CTMA), Institut de Recherche Exp\u00e9rimentale et Clinique (IREC), Universit\u00e9 Catholique de Louvain (UCLouvain), Brussels, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gabant","sequence":"additional","affiliation":[{"name":"Syngulon, Seraing, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"World Health Organization. WHO Publishes List of Bacteria for Which New Antibiotics are Urgently Needed 2017. Available at www.who.int\/mediacentre\/news\/releases\/2017\/bacteria-antibiotics-needed\/en\/"},{"key":"e_1_3_4_3_2","first-page":"Switzerland","article-title":"Global tuberculosis report 2020","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. 2020. Global tuberculosis report 2020. World Health Organization,, Geneva, Switzerland.","journal-title":"World Health Organization,"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8050639"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9080484"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.01205"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2019.00213"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr173"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033400"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2720-2722.2002"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3616-3619.2003"},{"key":"e_1_3_4_12_2","unstructured":"CLSI Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria Nocardia spp. and Other Aerobic Actinomycetes 3rd ed. CLSI standard document M24. Clinical and Laboratory Standards Institute Wayne PA. 2018."},{"key":"e_1_3_4_13_2","unstructured":"NC01CLS. Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. NCCLS Document M26-A. 1999. NCCLS 940 West Valley Road Suite 1400 Wayne Pennsylvania 19087 USA 1999."},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.07.036"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(93)90087-N"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2018.05.005"},{"key":"e_1_3_4_17_2","first-page":"Switzerland","article-title":"Antibacterial Agents in Clinical and Preclinical Development: An Overview and Analysis 2020","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. 2021. Antibacterial Agents in Clinical and Preclinical Development: An Overview and Analysis 2020. World Health Organization,, Geneva, Switzerland.","journal-title":"World Health Organization,"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph14040323"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.03.029"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2016.05.007"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-019-09771-6"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2014.01.014"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2011.09.031"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/np400145u"},{"key":"e_1_3_4_25_2","first-page":"5889","volume-title":"Angew. Chem. Int. Ed. Engl","author":"Schmitt E.K.","year":"2011","unstructured":"Schmitt E.K., , Riwanto M., , Sambandamurthy V., et al. 2011. The natural product cyclomarin kills Mycobacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease. Angew. Chem. Int. Ed. Engl. 50:5889\u20135891."},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176088"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1021\/ol502472c"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00359-18"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm053"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.02286-06"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2859-13-S1-S3"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05397-11"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.01827-08"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00808-10"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2836(02)00368-6"},{"key":"e_1_3_4_36_2","first-page":"95","article-title":"Bacteriocins - a viable alternative to antibiotics? Nat","volume":"11","author":"Cotter P.D.","year":"2013","unstructured":"Cotter P.D., , Ross R.P, , and C Hill. 2013. Bacteriocins - a viable alternative to antibiotics? Nat. Rev. Microbiol. 11:95\u2013105.","journal-title":"Rev. Microbiol"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fuaa039"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2021.0429","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2021.0429","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2021.0429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:40:09Z","timestamp":1777668009000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mdr.2021.0429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,1]]}},"alternative-id":["10.1089\/mdr.2021.0429"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2021.0429","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]}}}